- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02333513
A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation
April 8, 2015 updated by: Hebei Yanda Hospital
This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation.
And, this trial is approved by medical ethics committee of hebei yanda hospital.
Also, the trial has got a registry code "ChiCTR-OOC-15005759" in China clinical trial registry.
Researchers will conduct thsi trial from 2015/02 to 2017/12, and 100 recurrent high-grade glioma with IDH1/2 mutation patients will be recruited.
Patients who are recruited will get PCV chemotherapy in ether Hebei Yanda Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nan Ji, Medical Doctor
- Phone Number: +86 15210503095
- Email: neurochina@sohu.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Beijing Tiantan Hospital
-
Contact:
- Nan Ji, Medical Doctor
- Phone Number: +86 15210503095
- Email: neurochina@sohu.com
-
-
Hebei
-
Sanhe, Hebei, China, 065200
- Hebei Yanda Hospital
-
Contact:
- Nan Ji, Medical Doctor
- Phone Number: +86 15210503095
- Email: neurochina@sohu.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A diagnosis of high-grade glioma was established by pathological method,and the recurrency of the disease is ongoing.
- The report of the pathological diagnosis contained the status of IDH gene, and showed that IDH1/2 mutation existed.
- The age of the patient is between 18 years old and 70 years old.
- The condition of the patient permits the procedure of chemotherapy using PCV schema.
- The patient is informed consent, and willing to join in this research.
Exclusion Criteria:
- The diagnosis is not recurrent high-grade glioma.
- The diagnosis of high-grade glioma was not established by pathological method.
- No molecular neuropathological report is available, or the report showed that IDH1/2 mutation did not exist.
- The age of the patient does not meet the requirement of this research.
- The condition of the patient does not permit the procedure of chemotherapy using PCV schema.
- There are other conditions that the clinicians believe that the PCV chemotherapy is not appropriate for the patient.
- The patient is not willing to join in this research.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: case group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
progression free survival
Time Frame: 12 months or later
|
12 months or later
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
6-month progression-free survival rate
Time Frame: 6 month
|
6 month
|
12-month progression-free survival rate
Time Frame: 12 month
|
12 month
|
6-month survival rate
Time Frame: 6 month
|
6 month
|
12-month survival rate
Time Frame: 12 month
|
12 month
|
6-month life quality as measured by European Organization for the Research and Treatment of Cancer Quality of Life questionnaires(EORTC QLQ-C30,EORTC QLQ-BN20) and other methods
Time Frame: 6 month
|
6 month
|
12-month life quality as measured by European Organization for the Research and Treatment of Cancer Quality of Life questionnaires(EORTC QLQ-C30,EORTC QLQ-BN20) and other methods
Time Frame: 12 month
|
12 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Nan Ji, Medical Doctor, Beijing Tiantan Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2015
Primary Completion (Anticipated)
December 1, 2017
Study Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
January 6, 2015
First Submitted That Met QC Criteria
January 6, 2015
First Posted (Estimate)
January 7, 2015
Study Record Updates
Last Update Posted (Estimate)
April 9, 2015
Last Update Submitted That Met QC Criteria
April 8, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Recurrence
- Glioma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Phytogenic
- Vincristine
- Lomustine
- Procarbazine
Other Study ID Numbers
- YDCR-2014-006
- ChiCTR-OOC-15005759 (Registry Identifier: Chinese Clinical Trial Registry)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent High-grade Glioma
-
James FelkerConnor's Cure; Ellie Kavalieros Fund; Translational Brain Tumor Research FundActive, not recruitingNewly Diagnosed Pediatric Pontine Glioma | Newly Diagnosed Pediatric High Grade Glioma | Recurrent Pediatric High Grade Glioma | Recurrent Pediatric Low Grade GliomaUnited States
-
University of California, San FranciscoNovartis Pharmaceuticals; Pediatric Brain Tumor Foundation; The Lilabean Foundation...RecruitingHigh Grade Glioma | Low-grade Glioma | Recurrent World Health Organization (WHO) Grade II GliomaUnited States
-
Frank LiebermanUniversity of MinnesotaCompletedHigh Risk WHO Grade II Glioma | Recurrent/Post-Chemotherapy WHO Grade II GliomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
University of California, San FranciscoBeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II GliomaUnited States
-
Istituto Scientifico Romagnolo per lo Studio e...RecruitingHigh Grade Glioma | Malignant Glioma | Recurrent GliomaItaly
-
National Cancer Institute (NCI)CompletedChildhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Anaplastic Oligoastrocytoma | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood... and other conditionsUnited States, Canada
-
National Cancer Institute (NCI)RecruitingRecurrent WHO Grade 2 Glioma | Recurrent Low Grade Astrocytoma | Refractory Low Grade Astrocytoma | Refractory Low Grade Glioma | Refractory WHO Grade 1 GliomaUnited States, Canada
-
Susan ChangGE Healthcare; Sigma-Aldrich; Phillips-MedisizeRecruitingRecurrent WHO Grade III Glioma | WHO Grade III Glioma | WHO Grade II Glioma | Recurrent World Health Organization (WHO) Grade II GliomaUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | Recurrent High Grade Fallopian Tube Serous Adenocarcinoma | Recurrent High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma | Peritoneal High Grade...United States
Clinical Trials on Lomustine/Vincristine/Procarbazine
-
European Organisation for Research and Treatment...Medical Research CouncilCompletedBrain and Central Nervous System TumorsFrance, Switzerland, Netherlands, United Kingdom, Belgium, Germany, Italy, Sweden, Finland, Portugal, Austria, Hungary
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG Oncology; Eastern Cooperative Oncology Group and other collaboratorsCompletedBrain and Central Nervous System Tumors
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical... and other collaboratorsCompletedBrain and Central Nervous System TumorsUnited States
-
Institute of Cancer Research, United KingdomCompletedBrain and Central Nervous System TumorsUnited Kingdom
-
University Hospital HeidelbergRuhr University of Bochum; Universitätsmedizin MannheimRecruiting
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Indiana UniversityIndiana University Melvin and Bren Simon Cancer CenterCompletedBrain and Central Nervous System Tumors | Drug/Agent Toxicity by Tissue/Organ | Bone Marrow SuppressionUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Withdrawn
-
Incheon St.Mary's HospitalNational Cancer Center, KoreaUnknownRecurrent Glioblastoma MultiformeKorea, Republic of
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumors | Central Nervous System TumorsUnited States, Canada, Australia, Switzerland, Netherlands, New Zealand